Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

HemoGenyx Pharmaceuticals Plc (LSE:HEMO) in Focus: What the AIM Market Is Watching After 27 October 2026

HemoGenyx Pharmaceuticals Plc (LSE:HEMO) attracts attention through its exposure to experimental therapies and cell-based treatments.

Ankur Sharma | 28 October 2026

Ondine Biomedical, Inc. (LSE:OBI) in Focus: What the AIM Market Is Watching After 27 October 2026

Ondine Biomedical, Inc. (LSE:OBI) attracts attention through its exposure to photodisinfection technologies for infection prevention.

Ankur Sharma | 28 October 2026

NIOX’s Consumables Model Puts Clinical Adoption in Focus (LSE:NIOX)

NIOX Group plc (LSE:NIOX) is in focus for investors assessing the latest outlook for the healthcare sector as of 27 October 2026. The central question is not simply whether the business attracts attention, but whether its operating performance, financial position and near-term milestones can …

Ankur Sharma | 28 October 2026

PureTech’s Portfolio Progress Raises the Focus on Value Realisation (LSE:PRTC)

PureTech Health plc (LSE:PRTC) is in focus for investors assessing the latest outlook for the healthcare sector as of 27 October 2026. The central question is not simply whether the business attracts attention, but whether its operating performance, financial position and near-term milestones can …

Ankur Sharma | 28 October 2026

Can Bexmarilimab Keep Faron Pharmaceuticals (LSE:FARN) in Focus After Today's Gain?

Faron Pharmaceuticals Ltd is a Turku-based clinical-stage biopharmaceutical company developing immunotherapies for cancer, with shares quoted on AIM under the ticker LSE:FARN.

Ankur Sharma | 27 October 2026

Can Pre-Clinical Progress Sustain the Rally in HemoGenyx Pharmaceuticals Plc (LSE:HEMO)?

HemoGenyx Pharmaceuticals Plc (LSE:HEMO) gained 4.29% on 27 October 2026 as investors responded to news from its pre-clinical research programme. Early-stage pharmaceutical shares are highly sensitive to research updates. HemoGenyx focuses on disorders of the blood that represent significant unmet medical need, and progress …

Ankur Sharma | 27 October 2026

ImmuPharma Moves Higher as Lupus Pipeline Progress Draws Investor Interest — What Is Lifting LSE:IMM?

ImmuPharma plc (LSE:IMM) is a UK-listed clinical-stage biopharmaceutical company developing novel approaches to autoimmune diseases, with SLE as its primary indication. Its lead programme, Lupuzor, uses the P140 peptide, a tolerogenic immunotherapy designed to address the immune dysfunction driving lupus. On 27 October 2026, …

Ankur Sharma | 27 October 2026

Inspiration Healthcare Advances as Neonatal Care Demand Supports Growth — What Is Lifting LSE:IHC?

Inspiration Healthcare Group PLC (LSE:IHC) gained 8.11% on 27 October, 2026, as attention turned to its position in neonatal and critical care devices. The AIM-listed company supplies technologies used in neonatal units, emergency departments and critical care settings, serving premature and critically ill newborns …

Ankur Sharma | 27 October 2026

Eden BioSolutions Advances on Biopesticide Commercialisation Progress — What Is Behind the Move in LSE:EDEN?

Eden BioSolutions PLC (LSE:EDEN) is a UK-listed biopesticide developer bringing biological and naturally derived crop protection products to global agricultural markets. Its platform targets a structural shift away from synthetic chemical inputs toward solutions meeting tightening regulatory and consumer residue standards. On 27 October …

Ankur Sharma | 27 October 2026

EDX Medical Group Advances as Diagnostic Testing Expansion Gains Pace — What Is Behind LSE:EDX?

The advance appears to reflect company developments and sector tailwinds. A recent stock exchange announcement outlined progress in clinical testing partnerships, with new agreements enabling expanded testing volumes at several laboratory sites. The market responded to signs that the commercial pipeline is translating into …

Ankur Sharma | 27 October 2026
Support

Hi! How can we help you today?

Loading…